Conclusion
Adding BEV to traditional front-line or relapse therapy was safe in EOC. This strategy as maintenance therapy was effective in extending PFS and OS in advanced-stage patients. Platinum-sensitivity was the strongest prognostic factor. Platinum-sensitive relapsed EOC patients treated with BEV-added chemotherapy had a significant improvement in OS and had a longer duration in progressing to the next progression.
Ethics statement The Institutional Review Board of National Cheng Kung University Hospital approved the study protocol on 29 April 2019 (ref. no. B-ER-101-318). The study was performed in accordance with the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective nature of the study.
Disclosure of interests YFH got grants from the headquarters of the University Advancement at the National Cheng Kung University, which is sponsored by the Ministry of Education, Taiwan, ROC, during the conduct of the study. None of the funding sources were involved in collecting, analysing or interpreting data, writing the article or deciding to submit for publication. The other authors declare no competing interests. Full disclosure of interests is available to view online as supporting information.
Acknowledgments This research was carried out and administratively supported by NCKUH, College of Medicine, National Cheng Kung University. We acknowledge the efforts made by our nursing practitioners (Yu Hsiao Tai, Ya-Ting Chen, Ya-Ting Hu, Yueh-Chin Li, Shu-Jyun Wang, and Ya-Han Tsai) in assessing adverse effects related to chemotherapy or target therapies.